Table 2.

Patient details

Case number	Primary site, MIB-1 index	Prior therapies	Size of lesions (largest diameter)	Indication for sequential duo-PRRT	Cumulative dose and cycles of 177Lu-DOTATATE PRRT	Dose of 90Y-DOTATATE PRRT	Adverse effects	Follow-up period after sequential duo-PRRT
I	Mediastinal NET, 30%	Surgical resection of primary lesion, Somatostatin analog therapy and external beam radiotherapy	12 cm	Stable, unresponsive disease following 177Lu-DOTATATE	33.3 GBq, 5 cycles	2.7 GBq - First cycle	No	105 days
II	Pancreatic NET, 2%	Somatostatin analog therapy	8 cm	Progressive disease after 177Lu-DOTATATE	25.23 GBq, 4 cycles	2.8GBq-First cycle, 3.3 GBqsecond cycle	No	135 days
III	Duodenal NET, 10%	No prior therapies	10 cm	Stable, unresponsive disease following 177Lu-DOTATATE	31.59 GBq, 5 cycles	2.66 GBq - First cycle	No	135 days
IV	Pancreatic NET, 10 %	Surgical resection of primary lesion, somatostatin analog therapy	5.5 cm	Stable, unresponsive disease following 177Lu-DOTATATE	37 GBq, 6 cycles	3.14 GBq - First cycle	Transient mild-grade hemoglobin toxicity	105 days
V	Rectal NET, 12%	Somatostatin analog therapy	13 cm	Progressive disease after 177Lu-DOTATATE	22.2 GBq, 4 cycles	3.4 GBq- First cycle	Mild-grade of nausea	75 days
VI	Pancreatic NET, 1%	No prior therapies	5.5cm	Neoadjuvant intent	14.8 GBq, 2 cycles	3.25 GBq - First cycle	Mild-grade of nausea and gastrointestinal symptoms	75 days
VII	Pancreatic NET, 1%	Somatostatin analog therapy	7 cm	Stable, unresponsive disease following 177Lu-DOTATATE	32 GBq, 5 cycles	3.4 GBq - First cycle	No	60 days
VIII	Unknown primary site, 8%	No	13 cm	Stable, unresponsive disease following 177Lu-DOTATATE	37 GBq, 6 cycles	3.4 GBq - First cycle	No	30 days
IX	Duodenal NET, 8%	Surgical resection of primary lesion	16 cm	Neoadjuvant intent	11.84 GBq, 2 cycles	3.4GBq- First cycle	No	15 days

PRRT: Peptide receptor radionuclide therapy; NET: Neuroendocrine tumor; MIB: antibody directed at the protein Ki-67